Breaking News

Trials & Filings in Brief: Nov. 7, 2013

By Gil Roth | November 7, 2013

Agenus, Bayer, Celgene, Galderma, Genentech, NovaBay, Omeros, Regeneron, Roche

Phase I
Omeros TMA treatment well tolerated . . . read more

Phase II
Agenus posts good herpes vax results . . . read more

NovaBay impetigo treatment misses endpoint . . . read more

Phase III
Celgene to present Revlimid data at ASH . . . read more

Gazyva wallops Rituxan in CLL trial . . . read more

Filings
Bayer files for DME indication for Eylea . . . read more

blog comments powered by Disqus